Effects of Breast Cancer Stem Cell Extract Primed Dendritic Cell Transplantation on Breast Cancer Tumor Murine Models

Abstract

Cancer stem cells are considered as an origin of cancer. Cancer stem cells can cause tumors in mice models. Recent studies proved the efficacy of some promising therapies to treat cancers. Dendritic cell (DC) therapy is one of the best promising therapies to treat cancer. In recent years, DC therapy is performed by using primed cancer cell antigens of DC to immune organism body. This research aims to combine DC therapy with cancer stem cell antigen for treating breast cancer in murine models. DCs were derived from mouse bone marrow monocytes. Then they were primed with the breast cancer cell antigen prior to employ into the tumor mice model. This was performed to determine whether the DCs would capture and eventually migrate, be present in the spleen and present the cancer antigens to autologous CD8 T cells; induce the activation of the CTL response. The existence of tumors in mice was evaluated after 15-60 days from transplantation. The results showed that 40% mice of the experimental group, with injected breast cancer stem cell antigen loaded DCs, got tumors after 18 transplantation days. But in control group 100% mice got tumors after 15 transplantation days. It is also noticed that transplanted DCs could migrate into spleen, stimulate CD8 T cells and CD45 T cells proliferation. Specially, the ratio of CD8 T cells strongly increased in comparison to control or normal mice. These results are important and provides most required initial platform to do further experiment. Results of this study also established a promising novel targeting therapy for cancer, especially for breast cancer.